Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 27.47 $ -0.06 (-0.22 %)    

Monday, 09-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 27.46
$ 27.45 x 300
$ 27.48 x 200
-- - --
$ 24.53 - $ 38.80
369,343
na
2.55B
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

expert-ratings-for-genmab
Expert Ratings For Genmab
09/09/2024 14:00:57

truist-securities-maintains-buy-on-genmab-lowers-price-target-to-50
Truist Securities Maintains Buy on Genmab,...
09/09/2024 13:57:01

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $5...

morgan-stanley-reinstates-equal-weight-on-genmab-announces-31-price-target
Morgan Stanley Reinstates Equal-Weight on ...
09/04/2024 10:40:49

Morgan Stanley analyst Vikram Purohit reinstates Genmab (NASDAQ:GMAB) with a Equal-Weight and announces $31 price target.

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/27/2024 10:23:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

decoding-10-analyst-evaluations-for-genmab
Decoding 10 Analyst Evaluations For Genmab
08/20/2024 12:00:26

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/20/2024 11:09:43

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

jp-morgan-downgrades-genmab-to-neutral
JP Morgan Downgrades Genmab to Neutral
08/20/2024 10:36:30

JP Morgan analyst James Gordon downgrades Genmab (NASDAQ:GMAB) from Overweight to Neutral.

Core News & Articles
Genmab A/S Announces TEPKINLY Has Received...
08/19/2024 18:01:48

TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...

genmab-executive-vice-president-and-coo-anthony-mancini-decided-to-leave
Genmab Executive Vice President And COO An...
08/16/2024 13:07:02

on-holding-reports-mixed-q2-results-joins-tencent-music-entertainment-and-other-big-stocks-moving-lower-in-tuesday-pre-market-session
On Holding Reports Mixed Q2 Results, Joins...
08/13/2024 12:29:07

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/09/2024 21:24:40

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-updates-fy24-revenue-guidance-from-dkk-187b--205b-to-dkk-205b--217b-reflecting-continued-strong-growth-of-darzalex-and-kesimpta-net-sales
Genmab Updates FY24 Revenue Guidance From ...
08/08/2024 15:04:04

Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in o...

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/06/2024 11:29:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-rd-spending-on-new-cancer-products
BioNTech's Q2 Loss Widens Amid Low Demand ...
08/05/2024 11:59:26

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...

Core News & Articles
Genmab Takes Over Acasunlimab Development,...
08/05/2024 09:53:21

 Genmab A/S (NASDAQ: GMAB) announced today that it will assume sole responsibility for the continued development and potential ...

what-8-analyst-ratings-have-to-say-about-genmab
What 8 Analyst Ratings Have To Say About G...
08/01/2024 19:08:11

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
08/01/2024 10:07:01

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
07/18/2024 12:33:05

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

what-8-analyst-ratings-have-to-say-about-genmab
What 8 Analyst Ratings Have To Say About G...
07/15/2024 17:00:29

rbc-capital-upgrades-genmab-to-outperform
RBC Capital Upgrades Genmab to Outperform
07/15/2024 10:04:13

RBC Capital analyst Alistair Campbell upgrades Genmab (NASDAQ:GMAB) from Sector Perform to Outperform.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION